FIGURE 6.

(A) Number of agents per category and maximal reached phase. The number of discontinued and active agents per category. This graph presents information about unique agents and their maximal reached phase in the following classes: antidepressants, central nervous system stimulants, alpha2 adrenergic receptor agonists, AMPA receptor positive allosteric modulators, alpha7 neuronal nicotinic acetylcholine receptor agonists, antiparkinsonian, atypical antipsychotics, dementia therapeutic agents, histamine H3 receptor antagonists, nootropics, sedative-hypnotics, selective noradrenaline reuptake inhibitors, typical antipsychotics. The colors of the bars show the maximal reached phase or approval status. The right side of the graph depicts the number of active or discontinued agents in the classes presented on the left side. The drug was classified as active if it was not approved and there were clinical trials on it after 2018. The drug was classified as discontinued if it was not approved, and there were no active clinical trials on it after 2018. If there was no completion date for the agent, it was placed in the “without a date” category. The length of the bars is proportional to the number of agents. The colors of the bars show the agent category. (B) Ongoing trials and approved agents The pie charts show the distribution of drug classes in ongoing clinical trials and among approved ADHD agents. The colors of the slices correspond to the pharmacological classes. Trials have been sub-categorized by phase. The data is due 4 January 2021. Abbreviations: ADHD, attention deficit hyperactivity disorder; α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, AMPA receptor.